Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

serb - primidone - oral tablet - 250mg

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - primidone - oral tablet - 250mg

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

serb - primidone - oral tablet - 50mg

Australië - Engels - Department of Health (Therapeutic Goods Administration)

saramane pty ltd - malaria antigen msa-1 p190l, quantity: 12 microgram - injection, emulsion - excipient ingredients: sodium chloride; dibasic sodium phosphate dihydrate; monobasic sodium phosphate; thiomersal; squalane; squalene; peg-40 hydrogenated castor oil; mannide mono-oleate - vaccination against p.falciparum malaria

Verenigde Staten - Engels - NLM (National Library of Medicine)

stratatech corporation - viable and metabolically active allogeneic human niks keratinocytes and human dermal fibroblasts cellularized layered scaffold (unii: dyb2t93463) (viable and metabolically active allogeneic human niks keratinocytes and human dermal fibroblasts cellularized layered scaffold - unii:dyb2t93463) - stratagraft is an allogeneic cellularized scaffold product indicated for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns). do not use in patients with known allergies to murine collagen or products containing ingredients of bovine or porcine origin [see description (11)]. risk summary there are no available data regarding stratagraft use in pregnant women. no animal reproductive and developmental toxicity studies have been conducted with stratagraft to assess whether it can cause fetal harm when administered to a pregnant woman. in the united states general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there is no information available on the presence of stratagraft in human milk, the effect on the breastfed infant, or the effect on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for stratagraft and any potential adverse effects on the breast-fed infant from stratagraft or from the underlying maternal condition. the safety and effectiveness of stratagraft in pediatric patients (< 18 years) have not been established. eight patients aged 65 years and older were enrolled in study 1. although no differences in safety or efficacy were observed between patients aged 65 years and older and younger patients, the number of patients aged 65 years and older was not sufficient to determine whether they responded differently from younger patients.